Obecabtagene autoleucel is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Obecabtagene autoleucel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Obecabtagene autoleucel is expected to reach an annual total of $148 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Obecabtagene autoleucel Overview
Obecabtagene autoleucel is under development for the treatment of relapsed or refractory CD19 positive acute lymphoblastic leukemia in adults and pediatrics, diffuse large B cell lymphoma, B-cell acute lymphoblastic leukaemia, chronic lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary CNS lymphoma. It is administered as an intravenous infusion. The therapeutic candidate constitutes patient's own T cells transduced with lentiviral vector that have been genetically modified to express CD19CAT-41BBZ targeting CD19.
Autolus Therapeutics Overview
Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.
The company reported revenues of (US Dollars) US$2.3 million for the fiscal year ended December 2021 (FY2021), an increase of 35.9% over FY2020. The operating loss of the company was US$165 million in FY2021, compared to an operating loss of US$168.2 million in FY2020. The net loss of the company was US$142.1 million in FY2021, compared to a net loss of US$142.1 million in FY2020.
For a complete picture of Obecabtagene autoleucel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.